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ABSTRACT
Objective: The purpose of this study was to compare the efficacy and side effects of erythromycin,
amoxicillin, and clindamycin in eradicating Chlamydia trachomatis from the lower genital tract of
pregnant women.
Methods: A total of 174 women at <36 weeks gestation with positive cervical cultures for C.
trachomatis were enrolled. Patients were assigned in a randomized prospective fashion to either
erythromycin (500 mg q.i.d, for 7 days), amoxicillin (500 mg t.i.d, for 7 days), or clindamycin (600 mg
t.i.d, for 10 days). Six women elected not to participate and 8 patients were lost to follow-up, leaving
53 patients in the erythromycin group, 55 patients in the amoxicillin group, and 52 patients in the
clindamycin group. All sexual partners of the enrolled women were offered doxycycline (100 mg
b.i.d, for 7 days) and patients were instructed to use barrier contraception until treatment was
complete.
Results: All 3 medications were effective agents for the treatment of antenatal C. trachomatis
infection with treatment efficacies of 96%, 94%, and 98% for the erythromycin, amoxicillin, and
clindamycin groups, respectively. When the antibiotic groups were compared, no statistically signif-
icant differences were noted in intolerance. However, the differences in the incidence ofgastrointes-
tinal symptoms between erythromycin and amoxicillin and/or clindamycin were significant
(P < 0.05).
Conclusions: These findings suggest that 1) all 3 antibiotic regimens are efficacious, 2) erythromy-
cin has a higher incidence of side effects, and 3) amoxicillin or clindamycin are reasonable alterna-
tives for the treatment of C. trachomatis in pregnant patients unable to tolerate erythromycin.
(C) 1995 Wiley-Liss, Inc.
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hlamydia trachomatis is the most frequently en-
countered sexually transmitted disease in the
United States and is subsequently seen in preg-
nancy with a high prevalence. It has been estimated
that each year more than 155,000 infants are born
to women infected with C. trachomatis. The verti-
cal transmission of C. trachomatis can result in con-
junctivitis or pneumonia in up to 50% or 20% of
exposed infants, respectively.
2 Although erythro-
mycin has traditionally been the recommended an-
tibiotic to treat C. trachomat# during pregnancy,
it is poorly tolerated due to gastrointestinal side
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effects. Investigations into alternative antibiotic
therapies have shown that amoxicillin
3-5 and clin-
damycin
6 are efficacious in treating antenatal C.
trachomatis infections. Currently, the Centers for
Disease Control (CDC) guidelines recommend ei-
ther erythromycin or amoxicillin for treatment of
chlamydial infection in pregnancy. No compari-
son of erythromycin, amoxicillin, and clindamycin
in the treatment of C. trachomatis infection during
pregnancy has been reported. We conducted the
current study to determine, using a randomized
prospective design, the comparative efficacy of
erythromycin, amoxicillin, and clindamycin in
eradicating C. trachomatis from the lower genital
tract of pregnant women.
SUBJECTS AND METHODS
The study was approved by the institutional review
board of the University of Texas Health Science
Center--Houston. Women with cervical cultures
positive for C. trachomatis before 36 weeks gesta-
tion were eligible with the following exclusion cri-
teria: sensitivity to any of the study medications,
persistent gastrointestinal symptoms, or antibiotic
therapy after screening and before enrollment. A
randomized prospective trial was conducted, en-
rolling patients from the University of Texas Hos-
pital obstetrical clinic between July 1991 and Sep-
tember 1993.
After informed consent was obtained, each eligi-
ble patient was randomly assigned to of 3 treat-
ment groups: erythromycin-base tablets, 500 mg
q.i.d, orally for 7 days; amoxicillin capsules, 500
mg t.i.d, orally for 7 days; or clindamycin tablets,
600 mg t.i.d, orally for 10 days. The randomiza-
tion was accomplished by computer-generated as-
signment, and the unlabeled medications were dis-
pensed by the hospital pharmacy to prevent the
health-care team from learning the assigned medi-
cation. The partners of all participants received
doxycycline, 100 mg b.i.d, orally for 7 days. The
subjects were asked to abstain from sexual inter-
course or to use barrier contraception until both
members of the couple had completed their courses
of medication. The primary outcome variable was
defined as having completed the course of medica-
tion with a negative test-of-cure.
Four weeks after completion of the study medi-
cation, the patients had test-of-cure cultures from
the cervix. All patients were asked to return to the
clinic with their medication bottles for a pill count.
In addition, each patient was asked to complete a
questionnaire to document if 1) all medication was
taken, 2) any symptoms were noted while taking
the medication, and 3) her partner was treated.
The patients had test-of-cure cultures from the
cervix. All specimens were obtained from the endo-
cervical canal with plastic-handled, cotton-tipped
swabs after the ectocervix had been cleared of secre-
tions. Specimens for C. trachomatis were placed
immediately into transport media and processed
within 12 h. They were inoculated into cyclohexi-
mide-treated McCoy cells in shell-vial monolayers,
incubated for 48 h, fixed with ethanol, and stained
with fluorescein-conjugated monoclonal antibody
to C. trachomatis (Microtrak, Syva Co., Palo Alto,
CA). The inclusions were detected by fluorescence
microscopy. Any patient who had a positive test-of-
cure was contacted by telephone to assess if the
medication had been taken appropriately, if her
partner had been treated adequately, and if unpro-
tected intercourse had occurred after enrollment or
before the test-of-cure.
Statistical comparisons were performed using X2,
Fisher exact test, or t-test when appropriate;
P < 0.05 was regarded as significant.
RESULTS
A total of 174 eligible patients were enrolled in the
study (prevalence 6.4%); 6 women elected not to
participate. Ofthe 168 patients enrolled, 56 women
received erythromycin, 57 received amoxicillin,
and 55 received clindamycin. Eight patients were
lost to follow-up, 3 in the erythromycin, 2 in the
amoxicillin, and 3 in the clindamycin group, and
were excluded from the analysis. The demographic
characteristics of the patients in each treatment
group are shown in Table 1. There were no statis-
tically significant differences in age, racial distri-
bution, gravidity, gestational age, or number of
days to test-of-cure among the groups.
The success of the regimen was defined as com-
pleting the course of medication and having a neg-
ative test-of-cure culture. Forty-five of the 53
(85%) evaluable women assigned to the erythromy-
cin group successfully completed their regimens,
compared with 50 of the 55 (91%) women in the
amoxicillin group and 47 of the 52 (90%) women
in the clindamycin group (Fig. 1). These differ-
ences were not statistically significant.
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TABLE I. Demographic characteristics at enrollment
Erythromycin Amoxicillin Clindamycin
Age (years) 20.3 3.8 20.2 _+ 3.4 18.6 2.8
Race (% nonwhite) 64.4 68.0 74.5
Gravidity 2.2- 1.2 2.4-+ 1.2 1.9-+ 1.0
EGA (weeks) 24.3 _+ 6.6 24.9 _+ 6.3 22.9 _+ 6.2
Number of days to test-of-cure 35.9 -+ 8.7 31. -+ 9.3 34.7 _+ 9.0
aResults are mean -+ SD. No differences were statistically significant. EGA estimated gestational age.
Erythromycin Amoxicillin Clindamycin
Antibiotic
No differences statistically significant.
Negative test-of-cure for patients completing of medication
Number of patients completing the of medication and having
negative test-of-cure out of those assigned to the regimen.
Fig. I. Treatment efficacy.
Symptoms
I---I Intolerance
Erythromycin Amoxicillin Clindamycin
Antibiotic
.05 for symptoms
Symptoms include patients who intolerant to the medication.
Side effects enough to result in discontinuation of therapy
Fig. 2. Symptoms and intolerance.
Of the 53 patients in the erythromycin group,
developed an allergic reaction to erythromycin al-
though she had no history of an allergy. In addi-
tion, 13 women had gastrointestinal side effects due
to the erythromycin which resulted in 5 partici-
pants discontinuing the therapy. Of the remaining
47 patients, 45 (96%) had negative cervical cul-
tures after completing therapy. The 2 women who
failed treatment in the erythromycin group reported
having completed their medication. One ofthe fail-
ures admitted that her partner had not been treated
with doxycycline.
In the amoxicillin group, 55 patients were eval-
uated. Three women had gastrointestinal side ef-
fects due to amoxicillin which resulted in 2 discon-
tinuing the therapy. Fifty of the 53 (94%) patients
completing therapy had subsequent negative cervi-
cal cultures. All 3 women who failed treatment in
the amoxicillin group reported having completed
their treatment. Although all 3 women also re-
ported that their partners were not treated, 2 denied
having intercourse with their respective partners
since beginning their treatment.
In the clindamycin group, 52 patients were eval-
uated. Of these, 2 women developed an allergic
reaction to clindamycin although neither had any
history of an allergy. Five women had gastrointes-
tinal side effects due to clindamycin which resulted
in 2 discontinuing the therapy. Forty-seven of 48
(98%) patients completing therapy had subsequent
negative cervical cultures. The woman who failed
treatment in the clindamycin group reported com-
pletion of her treatment and compliance of her
partner with the doxycycline.
All 3 medication regimens, erythromycin, amox-
icillin, and clindamycin, were effective for the treat-
ment of antenatal C. trachomatis infection. Figure
shows that, with cure defined as a negative test-of-
cure culture for a patient completing treatment, the
treatment efficacies were 96%, 94%, and 98% for
the erythromycin, amoxicillin, and clindamycin
groups, respectively. These differences were not
statistically significant.
No life-threatening side effects were encoun-
tered in any of the antibiotic groups. Three patients
developed a rash to the medication (erythromy-
cin and clindamycin 2) which required the
discontinuation of therapy. Figure 2 shows the in-
cidence of intolerance (defined as side effects, such
as abdominal pain, emesis, and diarrhea, severe
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enough to result in the discontinuation of therapy)
and symptoms for the 3 antibiotic regimens. No
statistically significant differences were noted in
intolerance among all antibiotics. No differences in
the incidence of gastrointestinal symptoms due to
the treatment medication between the amoxicillin
or clindamycin group were significant. However,
the differences in the incidence of gastrointestinal
symptoms between erythromycin and amoxicillin
and/or clindamycin were significant (P < 0.05).
DISCUSSION
Traditionally, the recommended drug for the treat-
ment of antenatal C. trachomatis infections has been
the macrolide erythromycin. However, this med-
ication is typically poorly tolerated due to gas-
trointestinal side effects. Amoxicillin
3-s and clin-
damycin
6 have been recommended as alternative
regimens for the treatment of C. trachomatis in
pregnancy. Several studies
3-s have shown that
amoxicillin, 500 mg t.i.d, for 7 days, is as effective
as erythromycin in eradicating antenatal C. tra-
chomatis. Treatment efficacies of 82-9 8% have been
shown.-s Our result of 94% agrees with these
previous findings.
Clinical trials using clindamycin for the treat-
ment of C. trachomatis have been limited. Bowie et
al. v reported that a 7-day clindamycin regimen of
600 mg t.i.d, was only partially effective for the
treatment of chlamydial urethritis in men. How-
ever, Campbell and Dodson showed an 85% cure
rate in nonpregnant women with C. trachomatis
who took clindamycin, 450 mg q.i.d, for 10 days.
A similar treatment efficacy (94%) was demon-
strated by Alger and Lovchik
6 with antenatal C.
trachomatis infections in women who took clindamy-
cin, 450 mg q.i.d, for 14 days. In the current
study, a 10-day regimen of clindamycin was uti-
lized, and 98% of the women who completed the
therapy had negative tests-of-cure.
No previous study has compared both amoxicil-
lin and clindamycin with erythromycin for the treat-
ment of antenatal C. trachomatis. Using a random-
ized prospective study, we demonstrated that either
amoxicillin, 500 mg t.i.d, for 7 days, or clindamy-
cin, 600 mg q.i.d, for 10 days, was an effective
and well-tolerated regimen for the treatment of
antenatal chlamydial infections. Approximately
94% of the patients taking amoxicillin and 98% of
the patients taking clindamycin were cured. These
rates are similar to previous reports of amoxicil-
lin-s and clindamycin
6 used for the treatment of
antenatal chlamydial infections. A larger study
would be necessary to exclude the possibility of
[3-error and the superiority of amoxicillin or clin-
damycin.
Using the CDC-recommended dosage of eryth-
romycin for the treatment of antenatal C. tracho-
matis resulted in a large number of patients
(24.5%) experiencing gastrointestinal symptoms,
which was statistically different from the amoxicil-
lin (5.5%) and clindamycin (9.6%) groups. When
these 2 treatments were compared with erythromy-
cin, there was no significant difference in efficacy.
Similar results have been reported in studies com-
paring erythromycin with amoxicillin-s or clin-
damycin.
6 Although twice as many patients in the
current study experienced gastrointestinal side ef-
fects from erythromycin (9.4%) which resulted in
the discontinuation of therapy, this was not signifi-
cantly different from the amoxicillin (3.6%) or
clindamycin (3.8%) group. This finding is in con-
trast to that of Magat et al. ,4 who showed a statisti-
cal difference between erythromycin and amoxicil-
lin with regard to intolerance.
Our findings suggest that all 3 antibiotic regi-
mens are efficacious in the treatment of antenatal C.
trachomatis infections. Therefore, because erythro-
mycin has a higher incidence of side effects that
may result in the discontinuation of therapy, either
amoxicillin or clindamycin is a reasonable alterna-
tive for the treatment of C. trachomatis in pregnant
patients unable to tolerate erythromycin.
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